Celcuity Inc (CELC) reported a narrower loss for the third quarter of fiscal 2025, with earnings per share (EPS) of $-0.92, beating Wall Street's estimate of $-1.03 by $0.11. Revenue remained at $0.0B, aligning with analyst expectations.
The company's performance underscores its operational resilience as it navigates the biotechnology landscape. Celcuity, headquartered in Minneapolis, focuses on cellular analysis and is advancing its lead therapeutic candidate, gedatolisib, targeting advanced breast and prostate cancers.
The company will host an earnings conference call at AMC to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release for comprehensive context on the quarter's performance and future outlook.
Looking ahead, Celcuity's next earnings report is scheduled for May 12, 2026, with an EPS estimate of $-1.00 and revenue expected to remain at $0.0B.